This agent, which inhibits BCR-ABL, platelet-derived growth factor receptor (PDGFR) and c-KIT tyrosine kinases, has rapidly become established as the gold standard therapy for chronic myeloid leukaemia and gastrointestinal stromal tumours (GIST) (Druker, 2002). Here, KIT is linked to gastrointestinal stromal tumor.